Validating Antibodies for Research Applications in IHC

Will Howat, PhD, Director of Antibody Validation & Characterisation, Abcam
Damian Cockfield, Global Product Manager - BOND, Leica Biosystems

RELATED PRODUCTS
RELATED TAGS AND TOPICS
Automated IHC Workflow, Multiplex, Validation, Antibodies
SHARE

CONTACT YOUR RESEARCH EXPERT

The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high-quality specific results compared to spurious, non-specific antibody staining on tissue will be easier and allow the researcher to focus on downstream applications, such as single and multiplex IHC . This webinar will focus on the steps and challenges in antibody selection and validation to enable success and reproducibility in antibody staining in IHC .

 

Learning Objectives

  • How to select and validate antibodies for research applications in  IHC
  • Understand the reagents and tools available today to support the validation of antibodies for research applications in  IHC

Leica Biosystems content is subject to the Leica Biosystems website terms of use, available at: Legal Notice. The content, including webinars, training presentations and related materials is intended to provide general information regarding particular subjects of interest to health care professionals and is not intended to be, and should not be construed as, medical, regulatory or legal advice. The views and opinions expressed in any third-party content reflect the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents. Any links contained in the content which provides access to third party resources or content is provided for convenience only.

For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted.

Copyright © 2023 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.

About the presenters

Will Howat, PhD, Director of Antibody Validation & Characterisation, Abcam

Will Howat joined Abcam in August 2018 and is responsible for leading the global Imaging and Immunohistochemistry team. Prior to joining Abcam, he worked at AstraZeneca as the Team Leader of the Molecular Pathology Group, where his team developed biomarker assays for preclinical, Phase 1 and Phase 2 clinical trials. Before that he was at the Cancer Research UK Cambridge Institute where he set-up and ran the Histopathology/ISH core facility for 9 years. He has also worked at the Wellcome Sanger Institute on the Atlas of Protein Expression and was responsible for the R&D for the Immunohistochemistry group. Will has a BSc (Hons) in Immunology & Pharmacology from the University of Strathclyde and a PhD in Pathology from the University of Southampton. He has first-author publications in the Lancet, American Journal of Pathology and Journal of Pathology as well as co-authored publications in Nature, Science, Nature Genetics, and Journal of Experimental Medicine.

Damian Cockfield, Global Product Manager - BOND, Leica Biosystems

Damian is the Global Product Manager for the clinical and research BOND systems and is based in Melbourne, Australia. Damian joined Leica Biosystems as a Scientist in 2007 working on the development of BOND-III. Throughout his career at Leica Biosystems he has held numerous roles working across the broad portfolio of Leica Biosystems products, included spending 7 years based out of the Newcastle UK site before returning to Australia in 2018.